Fundies. English
Segment disclosures
Company overviewCelularity Inc
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
7 dimension combinations 100 retained observations 23 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Biobanking
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=celu:BiobankingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 1292000 | USD | 20241206 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 3857000 | USD | 20241206 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1278000 | USD | 20241107 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 2565000 | USD | 20241107 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 1287000 | USD | 20241016 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 5441000 | USD | 20240730 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1427000 | USD | 20241206 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 4062000 | USD | 20241206 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1278000 | USD | 20241107 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 2635000 | USD | 20241107 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 1357000 | USD | 20241016 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 5512000 | USD | 20240730 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 1405000 | USD | 20240103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 4061000 | USD | 20240103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 1373000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 2656000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 1283000 | USD | 20230522 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 5522000 | USD | 20230331 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 1343000 | USD | 20221110 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 4204000 | USD | 20221110 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1597000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 2861000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1264000 | USD | 20220525 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 5556000 | USD | 20220525 | Open filing evidence |
Biobanking
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=CELU:BiobankingMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 652000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1902000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 1250000 | USD | 20260929 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 5432000 | USD | 20260430 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 1448000 | USD | 20251114 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 4131000 | USD | 20251114 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1275000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 2683000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1408000 | USD | 20260929 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 5140000 | USD | 20260430 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 1292000 | USD | 20251114 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 3857000 | USD | 20251114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1278000 | USD | 20250829 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 2565000 | USD | 20250829 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 1287000 | USD | 20250829 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 5441000 | USD | 20250508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 1427000 | USD | 20250130 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 4062000 | USD | 20250130 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 5512000 | USD | 20250130 | Open filing evidence |
Cell Therapy
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=celu:CellTherapyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20220429 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220429 | Open filing evidence |
Cell Therapy
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=CELU:CellTherapyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1339000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1832000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 493000 | USD | 20260929 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 3807000 | USD | 20260430 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 1592000 | USD | 20251114 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 2615000 | USD | 20251114 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 759000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1023000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 264000 | USD | 20260929 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 688000 | USD | 20260430 | Open filing evidence |
Degenerative Disease
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=celu:DegenerativeDiseaseMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 8004000 | USD | 20241206 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 32231000 | USD | 20241206 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 10833000 | USD | 20241107 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 24227000 | USD | 20241107 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 13394000 | USD | 20241016 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 17330000 | USD | 20240730 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 2359000 | USD | 20241206 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6597000 | USD | 20241206 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 1660000 | USD | 20241107 | Open filing evidence |
| 2023-01-01 – 2023-06-30 | 4238000 | USD | 20241107 | Open filing evidence |
| 2023-01-01 – 2023-03-31 | 2578000 | USD | 20241016 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 12463000 | USD | 20240730 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 2730000 | USD | 20240103 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 9785000 | USD | 20240103 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 2403000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 7055000 | USD | 20230814 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 4652000 | USD | 20230522 | Open filing evidence |
| 2021-01-01 – 2021-12-31 | 15813000 | USD | 20230331 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 9279000 | USD | 20221110 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 12275000 | USD | 20221110 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 1600000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 2996000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1396000 | USD | 20220525 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 8722000 | USD | 20220525 | Open filing evidence |
Degenerative Disease
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=CELU:DegenerativeDiseaseMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 3441000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 5544000 | USD | 20261020 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 2103000 | USD | 20260929 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 17311000 | USD | 20260430 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 2244000 | USD | 20251114 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 15700000 | USD | 20251114 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 3702000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 13456000 | USD | 20261020 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 9754000 | USD | 20260929 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 48392000 | USD | 20260430 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 8004000 | USD | 20251114 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 32231000 | USD | 20251114 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 10833000 | USD | 20250829 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 24227000 | USD | 20250829 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 13394000 | USD | 20250829 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 17330000 | USD | 20250508 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 2359000 | USD | 20250130 | Open filing evidence |
| 2023-01-01 – 2023-09-30 | 6597000 | USD | 20250130 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 12463000 | USD | 20250130 | Open filing evidence |
Other
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=celu:OtherMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-01-01 – 2021-12-31 | 0 | USD | 20220429 | Open filing evidence |
| 2020-01-01 – 2020-12-31 | 0 | USD | 20220429 | Open filing evidence |